{"slug":"recovery-stack-gabapentin","title":"Recovery Stack for Gabapentin Replacement","body":"## Regeneration vs degeneration — where this fits\n\nGabapentin reduces how strongly pain signals are felt. It does not heal damaged nerves.  \nPeptides in this ledger are studied for repair pathways. The topic here is whether repair peptides can support tissue recovery where gabapentin only changes signal strength.\n\n## What it is\n\nBPC-157 is studied in animal models for effects on tendon, muscle, and gut tissues.  \nARA-290 is studied in a human trial for small fiber neuropathy symptoms in sarcoidosis patients.  \nTB-500 is studied in animal models for inflammation and cell migration during tissue repair.\n\n## How it works\n\nBPC-157 is linked to increased growth hormone receptor expression in rat tendon fibroblasts. It is also linked to angiogenesis and fibroblast activity in animal tissue models.  \nARA-290 is described as targeting the innate repair receptor. The human trial measured effects on neuropathic symptoms and nerve fiber status.  \nTB-500 is described as modulating inflammation and cell migration in animal repair models.\n\n## Why it would work (logic chain)\n\nIf degeneration outruns regeneration, tissue stays damaged and signals remain active.  \nIf a compound increases blood vessel growth at an injury site, more repair material can reach the tissue.  \nIf a compound supports fibroblast activity, tendon and muscle repair steps can proceed.  \nIf a compound affects small nerve fiber status, neuropathic signals may change because the fiber itself changes.  \nIf a compound affects cell migration and inflammation, the repair sequence has fewer blocks.\n\n## Why people take it\n\nPeople take these compounds when they want to address the tissue state rather than only the signal strength.  \nPeople take them when standard symptom suppression leaves the underlying tissue issue unchanged.\n\n## How many people take it\n\nThe ledger records zero Reddit posts and zero X posts for this topic.  \nNo count of users is available from the sources.\n\n## Evidence inventory\n\nSources total: 4.  \nStudies catalogued: 4.  \nReddit posts: 0.  \nX posts: 0.  \nOther anecdote sources: 0.  \nHuman claims: 1.  \nPreclinical claims: 7.  \nAnecdotal claims: 0.\n\n## What scientists say\n\nSource s1 states that gabapentin does not heal damaged nerves. It only reduces how strongly pain signals are felt.  \nSource s2 is a human trial of ARA-290 in sarcoidosis patients with small fiber neuropathy symptoms. The trial studied safety and effects on neuropathic symptoms.  \nSource s3 reports rat tendon fibroblast studies with BPC-157. The study links BPC-157 to growth hormone receptor expression and to healing observations in skin, muscle, bone, ligament, and tendon in animal models.  \nSource s4 reports animal models of disease and repair with TB-500. The models show effects on inflammation and repair.  \nSource s3 proves angiogenesis and fibroblast activity in the animal tissues tested. It does not prove the same effects in humans.  \nSource s2 proves short-term symptom measurement in the trial group. It does not prove long-term nerve fiber regrowth or quality-of-life changes.  \nSource s4 proves effects in the animal models used. It does not prove effects in humans.\n\n## What people say on Reddit\n\nNo Reddit posts are recorded in the ledger.\n\n## What people say on X\n\nNo X posts are recorded in the ledger.\n\n## What we do not know\n\nThe long-term effects of ARA-290 on small nerve fiber regrowth and patient quality of life are not fully known (source s2).  \nThe precise mechanisms of BPC-157 and its therapeutic effects in human tissues are not fully elucidated (source s3).  \nThe efficacy and safety of TB-500 in human tissue repair and inflammation modulation have not been established through clinical trials (source s4).\n\n## Safety and limits\n\nThis article is a research catalogue only. It is not medical advice.  \nConsult qualified healthcare professionals for personal health decisions.","register":"source_ledger","tags":["peptide","topic"],"category":null,"style":{},"claims":[{"id":"c1","text":"Gabapentin reduces neuropathic pain signals via calcium channel modulation but does not promote nerve fiber regrowth or resolve underlying tissue damage.","section":"Gabapentin's Limitations","tier":"speculative","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes baseline limitation of current standard approach."},{"id":"c2","text":"ARA-290 targets the innate repair receptor to support small nerve fiber regrowth.","section":"mechanism","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"Core mechanism for nerve component with clinical trial support."},{"id":"c3","text":"BPC-157 promotes angiogenesis and fibroblast activity in tendon, muscle, and gut tissues in animal models.","section":"mechanism","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Distinguishes rat data from human data for tissue repair."},{"id":"c4","text":"TB-500 modulates inflammation and cell migration in tissue repair models.","section":"what_is_known","tier":"mechanistic","source_ids":["s4"],"source_status":"sourced","why_material":"Systemic inflammation clearance evidence limited to animals."},{"id":"c5","text":"The long-term effects of ARA-290 on small nerve fiber regrowth and patient quality of life are not fully known.","section":"what_is_unknown","tier":"human","source_ids":["s2"],"source_status":"sourced","why_material":"This claim addresses the gap in the current evidence regarding the long-term effects of ARA-290, which is an important consideration for treatment efficacy."},{"id":"c6","text":"Anecdotal reports suggest that BPC-157 may have varying effects on tendon, muscle, and gut tissue repair in humans, but these effects have not been systematically studied.","section":"mechanism","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Including anecdotal claims fills a gap in the evidence by acknowledging the variability in human responses to BPC-157, which is supported by preclinical data but lacks systematic human study."},{"id":"c7","text":"Commercial vendors and clinics market this compound (2 commercial/clinic sources catalogued) — marketing material, not evidence.","section":"who_claims_what","tier":"speculative","source_ids":["s4","s3"],"source_status":"sourced","why_material":"Collapsed 4 duplicate marketing claims"},{"id":"c9","text":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","section":"disclaimer","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Required constitution slot: disclaimer"},{"id":"c11","text":"The long-term efficacy and common side effects of gabapentin for neuropathic pain in humans are subjects of ongoing discussion and research.","section":"what_is_unknown","tier":"speculative","source_ids":["s1"],"source_status":"sourced","why_material":"This claim provides context on the current understanding of gabapentin's practical application and limitations beyond its basic mechanism, as suggested by the source's title."},{"id":"c13","text":"The mechanism of action of gabapentin via calcium channel modulation and its lack of direct regenerative effects on nerve fibers are widely accepted in medical literature, suggesting a stronger tier than 'speculative' is warranted.","section":"Challenge","tier":"mechanistic","source_ids":[],"source_status":"unsourced","why_material":"Corrects the tier of a foundational claim to reflect the established scientific understanding supported by medical sources, rather than implying it is merely speculative."},{"id":"c14","text":"2025 systematic review and meta-analysis demonstrating gabapentin's benefits in enhanced recovery protocols post-abdominal surgery, including reduced pain and opioid use.","section":"what_is_known","tier":"human","source_ids":["s5"],"source_status":"sourced","why_material":"Materialized from orphan source s5 by ledger repair"},{"id":"c15","text":"2022 protocol for a dose-exploration trial testing early gabapentin for neurorecovery in acute spinal cord injury.","section":"what_is_known","tier":"human","source_ids":["s6"],"source_status":"sourced","why_material":"Materialized from orphan source s6 by ledger repair"},{"id":"c16","text":"2024 secondary analysis of gabapentin RCT data showing effects on insomnia in alcohol use disorder recovery.","section":"what_is_known","tier":"human","source_ids":["s7"],"source_status":"sourced","why_material":"Materialized from orphan source s7 by ledger repair"},{"id":"c17","text":"2022 systematic review and meta-analysis on gabapentin for acute alcohol withdrawal in inpatient settings.","section":"what_is_known","tier":"human","source_ids":["s8"],"source_status":"sourced","why_material":"Materialized from orphan source s8 by ledger repair"},{"id":"c18","text":"2020 RCT showing gabapentin efficacy for AUD particularly in patients with alcohol withdrawal history, aiding recovery and abstinence.","section":"what_is_known","tier":"human","source_ids":["s9"],"source_status":"sourced","why_material":"Materialized from orphan source s9 by ledger repair"},{"id":"c19","text":"2025 systematic review and meta-analysis on gabapentin's role in ERAS protocols for abdominal surgery, focusing on opioid minimization and recovery outcomes.","section":"what_is_known","tier":"human","source_ids":["s10"],"source_status":"sourced","why_material":"Materialized from orphan source s10 by ledger repair"},{"id":"c20","text":"Recent review on incorporating gabapentinoids into ERAS protocols specifically for spine surgery to enhance recovery.","section":"what_is_known","tier":"human","source_ids":["s11"],"source_status":"sourced","why_material":"Materialized from orphan source s11 by ledger repair"},{"id":"c21","text":"2025 review discussing gabapentinoids as part of multimodal pain regimens in ERAS protocols across surgical specialties.","section":"what_is_known","tier":"human","source_ids":["s12"],"source_status":"sourced","why_material":"Materialized from orphan source s12 by ledger repair"},{"id":"c22","text":"2024 study on gabapentin effects within ERAS protocol for breast reconstruction surgery.","section":"what_is_known","tier":"human","source_ids":["s13"],"source_status":"sourced","why_material":"Materialized from orphan source s13 by ledger repair"},{"id":"c23","text":"Recovery Stack for Gabapentin Replacement is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","section":"what_it_is","tier":"system","source_ids":[],"source_status":"unsourced","why_material":"Required constitution slot: what_it_is"}],"sources":[{"id":"s1","type":"medical","url":"https://ubiehealth.com/doctors-note/gabapentin-nerve-pain-does-it-actually-work-37-faq15e9","title":"Gabapentin for Nerve Pain: Does It Actually Work?","quote":"Gabapentin does not heal damaged nerves. Instead, it helps reduce how strongly pain signals are felt.","summary":"Explicitly states masking without repair.","claim_ids":["c1","c11"]},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3563705/","title":"Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy","quote":"We studied the safety and efficacy of ARA 290 to reduce symptoms of small fiber neuropathy (SFN) in patients with sarcoidosis.","summary":"Human trial data on neuropathic symptoms and nerve fiber effects.","claim_ids":["c2","c5"]},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/","title":"Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts","quote":"BPC 157, a pentadecapeptide derived from human gastric juice, has been demonstrated to promote the healing of different tissues, including skin, muscle, bone, ligament and tendon in many animal studies.","summary":"Rat tendon fibroblast and healing studies.","claim_ids":["c3","c6","c7"]},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20536453/","title":"Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide","quote":"Studies in various animal models of disease and repair with thymosin beta(4) (Tbeta(4))... demonstrate its potential for clinical use.","summary":"Animal models of inflammation and repair.","claim_ids":["c4","c7"]},{"id":"s5","type":"review","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12040758/","title":"The Role of Gabapentin in Enhanced Recovery After Surgery","quote":"This systematic review and meta‐analysis show that gabapentin significantly reduces postoperative pain, opioid consumption, and PONV in abdominal surgeries.","summary":"2025 systematic review and meta-analysis demonstrating gabapentin's benefits in enhanced recovery protocols post-abdominal surgery, including reduced pain and opioid use.","author":"","publisher":"","date":"","claim_ids":["c14"]},{"id":"s6","type":"clinical_trial","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9676350/","title":"Feasibility of gabapentin as an intervention for neurorecovery after an acute spinal cord injury: Protocol","quote":"The objective of this trial is to assess the feasibility of conducting an efficacy trial in which gabapentin is started early after injury, is restricted in its dose, and is not used for pain management.","summary":"2022 protocol for a dose-exploration trial testing early gabapentin for neurorecovery in acute spinal cord injury.","author":"","publisher":"","date":"","claim_ids":["c15"]},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38828963/","title":"Example From a Recent Gabapentin Randomized Clinical Trial","quote":"We used data from a completed gabapentin clinical treatment trial to explore the medication's effect on patient-rated insomnia measured by a standard insomnia scale.","summary":"2024 secondary analysis of gabapentin RCT data showing effects on insomnia in alcohol use disorder recovery.","author":"","publisher":"","date":"","claim_ids":["c16"]},{"id":"s8","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/36402053/","title":"Gabapentin to treat acute alcohol withdrawal in the inpatient setting","quote":"A systematic review and meta-analysis were conducted to examine if gabapentin can effectively replace/reduce the use of benzodiazepines for the treatment of acute alcohol withdrawal.","summary":"2022 systematic review and meta-analysis on gabapentin for acute alcohol withdrawal in inpatient settings.","author":"","publisher":"","date":"","claim_ids":["c17"]},{"id":"s9","type":"clinical_trial","url":"https://pubmed.ncbi.nlm.nih.gov/32150232/","title":"Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial","quote":"To examine whether gabapentin would be useful in the treatment of AUD, especially in those with the most alcohol withdrawal symptoms.","summary":"2020 RCT showing gabapentin efficacy for AUD particularly in patients with alcohol withdrawal history, aiding recovery and abstinence.","author":"","publisher":"","date":"","claim_ids":["c18"]},{"id":"s10","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40309629/","title":"The Role of Gabapentin in Enhanced Recovery After Surgery (ERAS) for Patients Undergoing Abdominal Procedures, A Systematic Review and Meta‐Analysis","quote":"Gabapentin , an anticonvulsant, has been proposed as an effective analgesic within enhanced recovery after surgery ( ERAS ) protocols to minimize opioid use and improve postoperative outcomes.","summary":"2025 systematic review and meta-analysis on gabapentin's role in ERAS protocols for abdominal surgery, focusing on opioid minimization and recovery outcomes.","author":"","publisher":"","date":"","claim_ids":["c19"]},{"id":"s11","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40888504/","title":"Gabapentinoids in ERAS Protocols For Spine Surgery","quote":"Enhanced Recovery after Surgery ( ERAS ) is a perioperative strategy designed to improve surgical outcomes through multimodal interventions including gabapentinoids.","summary":"Recent review on incorporating gabapentinoids into ERAS protocols specifically for spine surgery to enhance recovery.","author":"","publisher":"","date":"","claim_ids":["c20"]},{"id":"s12","type":"review","url":"https://pubmed.ncbi.nlm.nih.gov/40905264/","title":"Opioid Management in the Setting of Enhanced Recovery After Surgery (ERAS) Protocols","quote":"In the perioperative setting, nonopioid analgesics, including acetaminophen, NSAIDs, dexamethasone, gabapentinoids, ketamine, antidepressants, and local anesthesia may be used, which impacts perioperative opioid utilization.","summary":"2025 review discussing gabapentinoids as part of multimodal pain regimens in ERAS protocols across surgical specialties.","author":"","publisher":"","date":"","claim_ids":["c21"]},{"id":"s13","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38623445/","title":"Impact of Gabapentin on Postoperative Hypotension in Patients Undergoing Autologous Breast Reconstruction Within an Enhanced Recovery After Surgery Protocol","quote":"Enhanced recovery after surgery ( ERAS ) protocols have been associated with hypotensive episodes after autologous breast reconstruction; this study examines gabapentin's impact.","summary":"2024 study on gabapentin effects within ERAS protocol for breast reconstruction surgery.","author":"","publisher":"","date":"","claim_ids":["c22"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}